gabexate

gabexate

GI disease A small synthetic non-antigenic protease inhibitor used to prevent pancreatic damage related to ERCP; IV gabexate is associated with ↓ liver enzymes, pancreatic pain, acute pancreatitis. See ERCP.
References in periodicals archive ?
Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Gabexate mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury.
Therefore, most guidelines recommend against the use of immunemodulating therapies in SAP, such as anti-TNF[alpha] therapy (111), gabexate mesilate (112), lexipafant (113) or activated protein C (114).
Chemoprevention of post-FRCP pancreatitis has been achieved with gabexate, ulinastatin, indomethacin or octreotide.
Effect of nafamostat, gabexate, or gelatin on stabilization and efficacy of EGF.
Therefore, ulinastatin and gabexate mesilate, which possess both antifibrinolytic and anticoagulative effects, were administered (8,9).
Pharmaceutical approaches to inhibit pancreatic enzymes such as cimetidine, atropine, somatostatin, aprotinin and gabexate have not improved the outcome of the disease.